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rationing and rational health care resource allocation. Industry
does not like the notion of rationing, but it supports identifying
the best use of medicines in terms of the most appropriate
patients for the treatment and the most appropriate time in their
disease progression or treatment. There is a significant role for
BDA in working toward the aim of using biologics and biomarkers
in identifying most appropriate target populations and the opti-
mal time for treatment. Another key concept in HTA is reducing
uncertainty, which decreases as the number of clinical studies
evaluating safety and efficacy increases. HTA has a significant
impact on data requirements. Meeting the HTA hurdle requires
strong epidemiological evidence (i.e. the potential number of suit-
able patients), as well as an evidence-based position for the new
agent in therapy or clinical guidelines. Ideally data are also neces-
sary that identify the subpopulations that receive the greatest
clinical benefit. Investigation of the agent must be based on
meaningful endpoints and economic models must be transpar-
ent. Clinical trials must demonstrate its clinical efficacy and
safety. Real-world studies must identify its clinical effectiveness.
Finally, analysis of economic effectiveness of the agent must
demonstrate its budget impact, cost effectiveness, cost utility
and address equitable use. All supporting studies must include
an indication of evidence quality.
A ROLE FOR BIOMARKERS AND SURROGATE ENDPOINTS IN
HTA: How do clinical trial endpoints based on biomarkers figure
into the development and licensure scheme? Biomarkers are sur-
rogate endpoints that have substantial value in both clinical and
HTA evaluations of new products. Biomarkers can be used to
identify likely responding patients who have an abnormal condi-
tion prior to treatment initiation. They can also be used to assess
the extent of disease, monitor the safety of an intervention, and
evaluate the desired response.1
There are, however, some problems associated with reliance
on surrogate rather than clinical endpoints in trials of antican-
cer agents. First, one must understand under what circum-
stances a surrogate endpoint provides both a qualitative and
quantitative prediction of the clinical endpoint. Second, surro-
gate endpoints provide little or no information about the risk–
benefit profile of the product and scant quantitative evidence
of the magnitude of any effects on utility. For example, demon-
strating an anti-tumour agent’s significant effect on complete or
partial response rates may have little relationship to its effect on
either longevity or quality of life. The ultimate goal is to work
toward patient benefit and measuring outcomes that are mean-
ingful to, and valued by, the patient. Ideally the focus should
evolve from patient reported outcomes to patient relevant
outcomes.
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Demands are increasing on health care systems as the population
ages and competition heats up among numerous branches. What
data should serve as the basis for difficult decisions, and who
should make them? Various financial barometers signal that bur-
geoning needs and shrinking resources will lead to scarcity (or
perhaps, a perception of scarcity), and reimbursement is a central
part of scarcity steering. To balance needs with available
resources, wemust establish priorities based on state, association
and individual regulations.
Disease and scarcity are considered by people today to be
unconquerable and omnipresent. The greater the knowledge peo-
ple have of disease and its panoply of treatments, the greater is
their awareness of the gap between demand and resources. Inter-
estingly, the more society spends for disease management and
meeting health-care needs, the larger the scarcity appears to be.
Stated otherwise, being on the highest-ever level of material sup-
ply and per capita health-care spending for all ages in Europe, the
topic of scarcity is being discussed more heatedly than at any
other time.
For conventional cancer treatments for which response to
treatment depends on the duration of treatment, the greatest
value likely occurs near the beginning of treatment and decreases
over time. The interest of payers is in reducing cost, and the inter-
est of doctors and patients is in maximising treatment. Maximal
medical care, of course, has higher costs. Optimal treatment, in
an economic sense, occurs where the cost curve intersects the
curve representing decreasing medical benefits over time. Payers,
patients and doctors negotiate and compromise to arrive at the
point of economically optimised medical care.
Predictive markers must be developed for molecularly tar-
geted therapies to improve the benefit–cost relationship by only
treating patients with a high expectation of response. For regis-
tration or licensure of new products, alternatives to randomised
trials should be considered. Indirect comparisons might help
facilitate patient access to new medicines. Also, it is important
to keep in mind that molecularly targeted therapies mostly
involve small populations. Randomised trials require a great deal
of time, during which therapeutic options might change, thereby
compromising the value of the trial’s findings.
Academia, industry, regulators as well as patient advocacy
groups and economists will have to act in concert, and scientific
associations, suchas the BDAwill have to take active roles. Of para-
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mount importance is the requirement to keep public health care at
the highest scientific level, based on evidence and medical
competence.
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Risk–benefit analysis should be the only basis for approval or reg-
istration of a new agent. However in addition to this, in Sweden,
for example, there is an obligation to promote cost-effective use
of drugs based on written information or workshops that include
subscribers. The National Institute of Clinical Excellence (NICE), a
special health authority of the British National Health Service,
deals with issues of cost and reimbursement. Regulators may
think of considering cost effectiveness when they request data
to substantiate efficacy of new anticancer agents as long as
patients are provided with best possible treatment. If, however,
society is not prepared to pay for new products, then they should
not be developed.
The goal of regulators is to limit unnecessary queries because
they needlessly increase the price of new drugs. A tradeoff exists
between quality of data and cost and data quality cannot be
lowered below some point. Industry dislikes segmented pricing,
but, particularly in the case of drug combinations, costs are pro-
hibitive for many countries. Differential pricing, based on the
region where a drug is being marketed, is one way to maximise
income. Regulatory authorities should take this factor into
account as they consider registering or licensing new anticancer
therapies.
Oncology involves a very special group of drugs. Is a new drug
development model for oncology drugs required to get them to
the market more quickly? Is conditional or accelerated approval
the best means to do so? In theory, conditional approval should
work although it is a relatively new process. Linking conditional
approval to conditional reimbursement, however, needs to be
very carefully evaluated as it should be possible to reassess the
cost–benefit of a conditionally approved therapy and take it off
the market if the cost–benefit analysis is not favourable (although
it would be a very difficult situation).
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This discussion on pharmacoeconomics involves not only indus-
try and academia, but also real people who have cancer. Some
people are treated and cured, but many have to live with the dis-
ease. Results of a keypad voting survey1 regarding the patient
access to anticancer therapy of 104 cancer advocates in May
2005 are shown in Table 1.
Interestingly, 100% of respondents from France indicated they
knewof no onewhohad been refused access to a cancer treatment
because of cost, whereas 100% of those from Poland responded
that they did. Clearly, cost is a factor, and the ability to access
new anticancer therapies varies greatly across Europe. Patients
do not think like consumers, though, because they do not care
about price; they just want the best treatment.
Therefore the question is that if a significant number of people
in Europe are not able to access technologies, what is the point of
developing or testing them? To ensure that real people can benefit
from new drugs means eliminating barriers to access, which
include the high price tag of the drugs and the time it takes for
registration or licensure. Clinical trials, regulatory agency review
and health technology assessments (HTAs) all take time, but
patients with life-threatening disease often do not have that
luxury.
The goals of new-drug development should be to provide
patients everywhere with timely access to safe and effective ther-
apies and to ensure that patients are not put at undue risk by tak-
ing innovative medicines. Thanks to the informed consent
process, patients understand risk and many are willing to accept
it by participating in clinical trials, even if they might not benefit
directly. Nevertheless, placebo-controlled trials present chal-
lenges because patients generally desire the opportunity to take
a potentially effective drug. Patients are likely to benefit from
the regular monitoring provided during clinical trials, but their
Table 1 – Results of a keypad voting survey of cancer
advocates, 2005
Survey item Response (%)
Are you aware of any cancer drugs that are
not available in your country but are available in others?
Yes 54
No 46
If yes, why is the drug not available?
The drug(s) are not licensed in my country 39
The public health authority will
not reimburse the drug(s)
56
Physicians will not prescribe the drug 0
Do not know 5
Do you know of anyone who has been refused
access to a cancer treatment, because it was
considered too expensive?
Yes 51
No 49
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